Mission Statement, Vision, & Core Values (2026) of Tekla Healthcare Investors.

Founded on October 31, 1986, Tekla Healthcare Investors (HQH) is a closed-end equity fund from Tekla Capital Management that concentrates on biotechnology, medical devices, and pharmaceuticals, holding a diversified portfolio of over 50 healthcare companies from Johnson & Johnson to emerging biotechs and benchmarking performance against the NASDAQ Biotechnology Index, the S&P 500, and the S&P 1500 Healthcare Index; as of December 17, 2025, HQH trades at $18.80 (down $0.22, -1.16%), manages total net assets of $1.65 billion (Q3 2023), charges an expense ratio of 1.10%, and has demonstrated strong recent performance with a Q3 2023 year-to-date return of 12.3% and an annualized 2023 return of 12% versus an industry average of 8%, all driven by a mission to deliver high returns via rigorous fundamental analysis of market position, management quality, technology and financial health, a vision to lead healthcare investing with transparent quarterly reporting, and core values of integrity, innovation, collaboration and excellence that underpin its disciplined small-cap growth focus.

Tekla Healthcare Investors (HQH) - Intro

• Fund name: Tekla Healthcare Investors (HQH)
• Structure: Closed-end equity mutual fund
• Inception date: October 31, 1986
• Manager: Tekla Capital Management LLC
• Sector focus: Healthcare - biotechnology, medical devices, pharmaceuticals
• Typical market-cap focus: Primarily small-cap growth stocks, with positions across the cap spectrum
• Portfolio breadth: Investments in over 50 healthcare companies, from large-cap names (e.g., Johnson & Johnson) to emerging biotech firms
• Benchmark indices: NASDAQ Biotechnology Index, S&P 500 Index, S&P 1500 Healthcare Index
• Market quote (as of 2025-12-17): $18.80 per share, down $0.22 (-1.16%) from prior close

• Primary objective: Capital appreciation via concentrated, research-driven investments in healthcare innovators
• Stock selection: Fundamental analysis emphasizing market position, management quality, technology/clinical differentiation, and financial health
• Stage bias: High allocation to small-cap and emerging biotechs where clinical catalysts and product launches can drive outsized returns
• Risk management: Diversification across therapeutic areas and development stages; active position sizing and monitoring of clinical/regulatory timelines

• Large-cap exposure: Select positions in established healthcare companies (example: Johnson & Johnson)
• Core: Mid- and small-cap biotech and medtech firms with active pipelines or differentiated platforms
• Turnover: Active management with tactical rebalancing around clinical milestones and M&A activity

• Relative performance drivers: Clinical trial readouts, regulatory decisions, product launches, and M&A within the biotech/medical device ecosystem
• Volatility profile: Higher than broad-market indices due to concentration in small-cap biotech and event-driven exposures
• Benchmarking approach: Performance evaluated versus NASDAQ Biotechnology Index and broader indices (S&P 500, S&P 1500 Healthcare) to capture both sector-specific and market-wide context

• Quarterly reports and shareholder letters detailing portfolio changes, top holdings, and attribution
• Transparency around clinical and regulatory catalysts that are expected to drive short- to medium-term performance
• Use of NAV and market-price commentary to explain closed-end dynamics (premium/discount drivers)

Tekla Healthcare Investors (HQH) - Overview

• Primary objective: capital appreciation via active exposure to healthcare innovation and durable healthcare franchises.
• Investment approach: bottom-up fundamental analysis focusing on market position, management quality, technological expertise, and financial health.
• Diversification: allocation across subsectors (biotech, devices, pharma, services) to mitigate idiosyncratic risk while preserving upside from innovation.

• Research Rigor - independent, repeatable fundamental analysis drives every investment decision.
• Investor Alignment - transparent reporting, fee discipline, and fiduciary focus on long-term performance.
• Risk Awareness - active diversification and position-sizing to balance innovation exposure with capital preservation.
• Ethical Stewardship - engagement with management teams and support for responsible healthcare advancement.

• Concentrated, research-driven positions sized to reflect conviction and downside risk.
• Broad subsector exposure to capture multiple innovation vectors while reducing single-asset idiosyncrasy.
• Regular rebalancing tied to valuation, clinical/approval catalysts, and fundamentals shifts.

Tekla Healthcare Investors (HQH) - Mission Statement

• Invest across early-stage biotech, mid-stage medical device innovators, and established pharmaceutical companies to balance growth and stability.
• Pursue long-term capital appreciation with disciplined portfolio construction and sector diversification.
• Align fund performance with relevant industry benchmarks and maintain clear, regular investor communication.

• Benchmark alignment: NASDAQ Biotechnology Index, S&P 500 Index, S&P 1500 Healthcare Index.
• Reporting cadence: Quarterly reports with holdings, NAV movements, sector exposure, and risk metrics.
• Governance: Independent oversight, clear fee disclosure, and shareholder-friendly practices.

• Scientific and financial rigor - investment decisions grounded in clinical data and fundamental analysis.
• Transparency - full disclosure of holdings, fees, and performance on a regular basis.
• Risk-aware innovation - capture upside from breakthrough therapeutics while managing concentration and liquidity risks.
• Investor alignment - fee structures and communication designed to reflect shareholder interests.

• Quarterly investor reports detailing NAV, sector exposures, top holdings, realized/unrealized gains, and risk statistics.
• Regular commentary on regulatory developments, clinical trial outcomes, and M&A activity affecting portfolio companies.
• Active shareholder engagement and proxy voting consistent with long-term value creation.

Tekla Healthcare Investors (HQH) - Vision Statement

• Integrity - transparency and accountability in reporting, governance, and stakeholder communications underpin all investment decisions.
• Innovation - active sourcing and conviction in emerging therapeutics, diagnostics, digital health and medtech to capture secular healthcare growth.
• Collaboration - working closely with portfolio management teams, industry experts and company leadership to create synergies and accelerate value realization.
• Excellence - disciplined research, strict risk controls and continuous performance improvement to deliver superior outcomes for investors.

• Rigorous due diligence - multi‑disciplinary research teams evaluate clinical data, regulatory pathways, reimbursement scenarios and commercial scalability; this process has contributed to the portfolio's 4.5‑star average rating from independent analysts.
• Active risk management - position sizing, sector rotation and downside stress testing aim to protect capital while pursuing growth; 2023 results (12% annualized) demonstrate outperformance vs. the 8% industry benchmark.
• Portfolio construction - concentration into high‑conviction names balanced by exposure across sub‑sectors: biologics, biotech, medical devices, diagnostics and healthcare services.
• Engagement & collaboration - proactive corporate engagement and collaboration with management teams to drive operational improvements and strategic execution.